Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 18,500 shares at $157.62 ($2.9M) on 2018-08-13, disclosed to the SEC on 2018-08-15.
Open-market sale of $2.9M LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $157.62 | 730 | $115K | 3.9% |
| 2 | $157.62 | 730 | $115K | 3.9% |
| 3 | $158.66 | 3,070 | $487K | 16.5% |
| 4 | $158.66 | 3,070 | $487K | 16.5% |
| 5 | $159.69 | 1,500 | $240K | 8.1% |
| 6 | $160.59 | 200 |
| $32K |
| 1.1% |
| 7 | $160.60 | 200 | $32K | 1.1% |
| 8 | $159.08 | 600 | $95K | 3.2% |
| 9 | $159.08 | 600 | $95K | 3.2% |
| 10 | $159.91 | 3,199 | $512K | 17.4% |
| 11 | $159.91 | 3,199 | $512K | 17.4% |
| 12 | $160.70 | 701 | $113K | 3.8% |
| 13 | $160.70 | 701 | $113K | 3.8% |
| Total | $159.32 avg | 18,500 | $2.9M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |